Diffusion-Weighted Intravoxel Incoherent Motion Imaging of Renal Tumors With Histopathologic Correlation
Authors:
- Hersh ChandaranaHCHersh Chandarana
- Stella K. KangSKStella K. Kang
- Samson WongSWSamson Wong
- Henry RusinekHRHenry Rusinek
- Jeff L. ZhangJZJeff L. Zhang
- Shigeki ArizonoSAShigeki Arizono
- William C. HuangWHWilliam C. Huang
- Jonathan MelamedJMJonathan Melamed
- James S. BabbJBJames S. Babb
- Edgar F. SuanESEdgar F. Suan
- Vivian S. LeeVLVivian S. Lee
- Eric E. SigmundESEric E. Sigmund
- 1 December 2012
- journal article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 47 (12) , 688-696
Abstract
The aim of this study was to use intravoxel incoherent motion diffusion-weighted imaging to discriminate subtypes of renal neoplasms and to assess agreement between intravoxel incoherent motion (perfusion fraction, fp) and dynamic contrast-enhanced magnetic resonance imaging (MRI) metrics of tumor vascularity. In this Health Insurance Portability and Accountability Act-compliant, institutional review board-approved prospective study, 26 patients were imaged at 1.5-T MRI using dynamic contrast-enhanced MRI with high temporal resolution and diffusion-weighted imaging using 8 b values (range, 0-800 s/mm). Perfusion fraction (fp), tissue diffusivity (Dt), and pseudodiffusivity (Dp) were calculated using biexponential fitting of the diffusion data. Apparent diffusion coefficient (ADC) was calculated with monoexponential fit using 3 b values of 0, 400, and 800 s/mm. Dynamic contrast-enhanced data were processed with a semiquantitative method to generate model-free parameter cumulative initial area under the curve of gadolinium concentration at 60 seconds (CIAUC60). Perfusion fraction, Dt, Dp, ADC, and CIAUC60 were compared between different subtypes of renal lesions. Perfusion fraction was correlated with CIAUC60. We examined 14 clear cell, 4 papillary, 5 chromophobe, and 3 cystic renal cell carcinomas (RCCs). Although fp had higher accuracy (area under the curve, 0.74) for a diagnosis of clear cell RCC compared with Dt or ADC, the combination of fp and Dt had the highest accuracy (area under the curve, 0.78). The combination of fp and Dt diagnosed papillary RCC and cystic RCC with 100% accuracy, and clear cell RCC and chromophobe RCC, with 86.5% accuracy. There was significant strong correlation between fp and CIAUC60 (r = 0.82; P < 0.001). Intravoxel incoherent motion parameters fp and Dt can discriminate renal tumor subtypes. Perfusion fraction demonstrates good correlation with CIAUC60 and can assess degree of tumor vascularity without the use of exogenous contrast agent.Keywords
This publication has 53 references indexed in Scilit:
- Investigation of renal lesions by diffusion-weighted magnetic resonance imaging applying intravoxel incoherent motion-derived parameters—Initial experienceEuropean Journal of Radiology, 2012
- Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: Evaluation of a revised monoexponential model within a clinical settingJournal of Magnetic Resonance Imaging, 2011
- Resolving arterial phase and temporal enhancement characteristics in DCE MRM at high spatial resolution with TWIST acquisitionJournal of Magnetic Resonance Imaging, 2011
- Intravoxel Incoherent Motion MRI for the Differentiation Between Mass Forming Chronic Pancreatitis and Pancreatic CarcinomaInvestigative Radiology, 2011
- Statistical evaluation of diffusion‐weighted imaging of the human kidneyMagnetic Resonance in Medicine, 2010
- MRI quantification of non‐Gaussian water diffusion by kurtosis analysisNMR in Biomedicine, 2010
- Variability of Renal Apparent Diffusion Coefficients: Limitations of the Monoexponential Model for Diffusion QuantificationRadiology, 2010
- Optimal k‐space sampling for dynamic contrast‐enhanced MRI with an application to MR renographyMagnetic Resonance in Medicine, 2009
- Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell CarcinomaClinical Cancer Research, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007